Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20328418 | 0.85 | TDP1 (0.66) | HTTTDP1ALDH1A1LMNAGPR35 | |
| SCHEMBL397931 | 0.85 | TDP1 (0.66) | HTTTDP1ALDH1A1LMNAGPR35 | |
| SCHEMBL20328412 | 0.85 | TDP1 (0.66) | HTTTDP1ALDH1A1LMNAGPR35 | |
| SCHEMBL29351649 | 0.85 | TDP1 (0.66) | HTTTDP1ALDH1A1LMNAGPR35 | |
| SCHEMBL527567 | 0.84 | HTT (0.72) | HTTTDP1ALDH1A1LMNAPKM | |
| SCHEMBL29441283 | 0.84 | HTT (0.72) | HTTTDP1ALDH1A1LMNAPKM | |
| SCHEMBL11224598 | 0.82 | CHEK1 (0.61) | TDP1ALDH1A1LMNASIRT6L3MBTL1 | |
| SCHEMBL28153531 | 0.81 | TDP1 (0.62) | HTTTDP1ALDH1A1LMNAGPR35 | |
| SCHEMBL10363811 | 0.81 | TTR (0.67) | HTTTDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL57125 | 0.81 | HTT (0.68) | HTTTDP1ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-85108951-A | The novel synthesis of 4-nitro-benzene-beta-methoxy-ether | — | 1986-10-08 | — | — | CN | claimed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | claimed |
| CN-114042157-B | Photosensitive vitreous injectable gel and preparation method and application thereof | 江苏省中医药研究院 | 2023-10-27 | — | — | CN | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114042157-A | Photosensitive vitreous injectable gel and preparation method and application thereof | 江苏省中医药研究院 | 2022-02-15 | — | — | CN | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-5500060-A | IMPROVED SAFETY RELATED TO UNWANTED IGNITION, NITRAMINE COMPOUNDS, AROMATIC NITRO COMPOUNDS | ROYAL ORDNANCE PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | HTT 460/4885TDP1 597/4885ALDH1A1 1331/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | HTT 460/4885TDP1 597/4885ALDH1A1 1331/4885 |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | HTT 1801/4885TDP1 42/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.